Alcon (ALC)
Builds surgical eye-care systems, contact lenses, and ocular-health products for global markets.
Something off on this page? Send us feedback.
Develops surgical eye-care systems, implantables, and recurring procedure supplies while selling contact lenses and ocular-health products through Vision Care. The global model links equipment placements to consumable demand and depends on regulatory clearance, procedure volumes, supply continuity, clinical adoption, and professional and retail channels.
Develops eye-care products across two businesses: Surgical and Vision Care. Surgical supplies equipment, intraocular lenses, glaucoma devices, and recurring consumables for cataract, vitreoretinal, refractive-laser, and glaucoma procedures.
Sells daily and reusable contact lenses alongside lens-care, dry-eye, allergy, vitamin, redness-relief, and selected ophthalmic pharmaceutical products. Operations span more than 140 countries, with a Swiss headquarters and major operating and innovation activities in Fort Worth.
Combines internal research with acquisitions and product extensions, while installed surgical systems support recurring demand for proprietary supplies. Results depend on regulatory clearances, clinical adoption, procedure volumes, manufacturing quality, supply continuity, and professional, retail, distributor, and e-commerce channels.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Jefferies | Reiterate | Rating: —Target: $105 | Target: $85 |
| Aug 13, 2026 | Exane BNP Paribas | Downgrade | Rating: — | |
| Aug 13, 2026 | BNP Paribas | Target | Target: — | Target: $79 |
| Aug 12, 2026 | UBS | Target | Target: $91 | Target: $35 |
| Aug 12, 2026 | Mizuho Securities | Target | Target: $80 | Target: $85 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.46B · Total debt $5.30B · Total assets $31.10B · Shareholders' equity $21.60B
- Revenue
- $2.82B
- Operating income
- $11.0M
- Net income
- $0
HistoryDividendAnnual yield
| Institutions | 49.34% | 240.65M ADS | |
|---|---|---|---|
| 668 holders · as of Jun 30, 2026 | |||
| Strategic holders | 5.29% | 25.78M ADS | |
| 1 holder · as of Feb 13, 2024 | |||
| Other | 45.37% | 221.27M ADS | |
| remainder | |||
487.70M ADS as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Capital Research Global InvestorsInstitution | 6.53% | 31.82M | filed Feb 14, 2020 |
WCM Investment Management, LLCInstitution | 5.33% | 26.02M | filed Feb 10, 2022 |
Management division of UBS Group AGStrategic | 5.29% | 25.78M | filed Feb 13, 2024 |
Vanguard Capital Management LLCInstitution | 3.02% | 14.75M ADS | as of Jun 30, 2026 |
Bank of New York Mellon CorpInstitution | 2.68% | 13.06M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Bausch + Lomb
Broad rival in lenses, ocular health, and ophthalmic surgery
- Johnson & Johnson
Competes across contact lenses and cataract implants
- CooperCompanies
Major contact-lens rival across daily and reusable modalities
- Glaukos
Focused rival in interventional glaucoma therapies
- STAAR Surgical
Focused refractive-surgery rival through implantable phakic lenses
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alcon | $65.51 | +0.99% | $31.64B | 49.9 | 17.2 | 2.9 | +7.5% |
| Bausch + Lomb | $17.23 | +2.56% | $6.00B | — | 17.3 | 1.1 | +9.1% |
| Johnson & Johnson | $269.07 | −0.15% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| CooperCompanies | $55.33 | +2.24% | $10.56B | 18.5 | 12.1 | 2.5 | +0.6% |
| Glaukos | $162.10 | +0.35% | $9.53B | — | 1,265.3 | 15.5 | +49.5% |
| STAAR Surgical | $20.33 | +0.06% | $1.01B | 254.0 | 35.3 | 3.0 | +111.0% |
| Median | 31.2 | 22.7 | 3.0 | +9.1% |